Latest Medical Devices News

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

Universal Biosensors Pty Limited has entered voluntary administration with KPMG appointed as administrators, signaling urgent financial distress and a potential restructuring ahead.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

ResMed Inc has updated the foreign exchange rate for its forthcoming dividend payable to ASX-listed CDIs, setting the Australian dollar payout at 9.24 cents per CDI. This adjustment reflects the latest USD to AUD exchange rate and carries important tax implications for investors.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.

Cochlear Limited has extended its on-market share buy-back program, allowing the company to repurchase up to AUD 75 million of its fully paid ordinary shares until August 2026.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

Vitasora Health has expanded its partnership with Tampa Family Health Centers to deliver chronic care and remote monitoring services to 7,000 Medicaid patients, unlocking over US$4 million in annual revenue. This marks a pioneering step for Florida’s largest Federally Qualified Health Center in adopting value-based care for underserved communities.